Entero Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGEntero Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings contraction of 14% provides fundamental context to the price action. Investors should exercise caution due to high volatility (171% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.94 | -27.68% | BELOW |
| 50 SMA | $3.23 | -11.78% | BELOW |
| 100 SMA | $3.73 | -23.64% | BELOW |
| 150 SMA | $3.04 | -6.20% | BELOW |
| 200 SMA | $2.60 | +9.67% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ENTO in an uptrend right now?
ENTO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ENTO overbought or oversold?
ENTO's RSI (14) is 42. The stock is in neutral territory, neither overbought nor oversold.
Is ENTO outperforming the market?
ENTO has a Relative Strength (RS) Rating of 89 out of 99. Yes, ENTO is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is ENTO in its 52-week range?
ENTO is trading at $2.85, which is 49% of its 52-week high ($5.84) and 37% above its 52-week low ($1.08).
How volatile is ENTO?
ENTO has a Beta of 0.83 and 52-week volatility of 171%. It's less volatile than the S&P 500 - generally more stable.